Nov 21, 2018 • 7:00am EST

Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development

-- Single Phase 3 Clinical Trial May be Sufficient for Approval for Prevention of Antibiotic-Mediated Clostridium difficile Infection (CDI) -- -- SYN-004 (ribaxamase) is in Development as Potentially the First Intervention Designed to Specifically Prevent Antibiotic Damage to the Microbiome -- ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 (ribaxamase) for ...